ZA200708086B - Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands - Google Patents

Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Info

Publication number
ZA200708086B
ZA200708086B ZA200708086A ZA200708086A ZA200708086B ZA 200708086 B ZA200708086 B ZA 200708086B ZA 200708086 A ZA200708086 A ZA 200708086A ZA 200708086 A ZA200708086 A ZA 200708086A ZA 200708086 B ZA200708086 B ZA 200708086B
Authority
ZA
South Africa
Prior art keywords
dementia
parkinson
disease
treatment
sleep apnea
Prior art date
Application number
ZA200708086A
Other languages
English (en)
Inventor
Schwartz Jean-Charles
Lecomte Jeanne-Marie
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35169680&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200708086(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of ZA200708086B publication Critical patent/ZA200708086B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200708086A 2005-04-01 2007-09-20 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands ZA200708086B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05290727A EP1707203A1 (en) 2005-04-01 2005-04-01 Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands

Publications (1)

Publication Number Publication Date
ZA200708086B true ZA200708086B (en) 2008-10-29

Family

ID=35169680

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200708086A ZA200708086B (en) 2005-04-01 2007-09-20 Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands

Country Status (27)

Country Link
US (1) US8486947B2 (enExample)
EP (2) EP1707203A1 (enExample)
JP (3) JP5546761B2 (enExample)
KR (1) KR101308527B1 (enExample)
CN (1) CN101171009B (enExample)
AU (1) AU2006228413C1 (enExample)
BR (1) BRPI0612216B1 (enExample)
CA (1) CA2603656C (enExample)
CY (1) CY1114636T1 (enExample)
DK (1) DK1863487T4 (enExample)
EA (1) EA016007B1 (enExample)
ES (1) ES2426008T5 (enExample)
HR (1) HRP20130748T4 (enExample)
MA (1) MA29353B1 (enExample)
ME (1) ME01713B (enExample)
MX (1) MX2007012162A (enExample)
NO (1) NO343603B1 (enExample)
NZ (1) NZ561940A (enExample)
PL (1) PL1863487T5 (enExample)
PT (1) PT1863487E (enExample)
RS (1) RS52911B2 (enExample)
SG (1) SG147415A1 (enExample)
SI (1) SI1863487T2 (enExample)
TN (1) TNSN07365A1 (enExample)
UA (1) UA94902C2 (enExample)
WO (1) WO2006103546A2 (enExample)
ZA (1) ZA200708086B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2655604C (en) 2006-06-23 2016-08-09 Abbott Laboratories Cyclopropyl amine derivatives
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
FR2903904A1 (fr) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile Association de modafinil et d'un antagoniste ou agoniste inverse du recepteur h3
EP2502918B1 (en) 2006-07-25 2015-03-25 Cephalon, Inc. Pyridazinone Derivatives
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
EP2250176B1 (en) 2008-01-30 2012-08-01 Cephalon, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
FR2932479A1 (fr) 2008-06-13 2009-12-18 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8853390B2 (en) 2010-09-16 2014-10-07 Abbvie Inc. Processes for preparing 1,2-substituted cyclopropyl derivatives
US9181275B2 (en) 2011-08-11 2015-11-10 Abbvie Inc. Mercaptoamidine derivatives and methods of use
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
KR20150064743A (ko) * 2012-10-05 2015-06-11 트랜스테크 파르마 엘엘씨 경도 및 중등도 알츠하이머 병의 치료
EP3391886A1 (en) 2017-04-19 2018-10-24 Novartis AG The use of a h3r inverse agonist for the treatment of shift work disorder
US20200281522A1 (en) 2019-03-06 2020-09-10 Medtronic Xomed, LLC System and method for improved obstructive sleep apnea diagnostic for implantable devices
EP4248969A1 (en) 2022-03-23 2023-09-27 Bioprojet Use of pitolisant for treating severe fatigue
JP2026511788A (ja) 2023-03-31 2026-04-14 ビオプロジェ・ファルマ ピトリサント塩酸塩の多形形態
CN122374013A (zh) 2023-10-16 2026-07-10 生物计划制药公司 替洛利生的新制剂和使用方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5815945A (ja) * 1981-07-21 1983-01-29 Teikoku Hormone Mfg Co Ltd 新規なフエノキシアルキルアミン誘導体
FR2579596B1 (fr) 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
EP0573542B1 (en) 1991-02-27 1997-10-15 Seed Capital Investments( Sci) B.V. Imidazole-derivatives having antagonistic activity on the histamine h3-receptor
NZ246434A (en) 1991-12-18 1996-02-27 Schering Corp Imidazoylalkyl substituted by a six membered nitrogen containing heterocycle; pharmaceutical compositions and preparatory methods
DE69212844T2 (de) 1991-12-18 1997-01-09 Schering Corp., Kenilworth, N.J. Imidazolyl oder imidazolylalkyl substituiert mit einem 4- oder 5-gliedrigen stickstoff enthaltenden heterozyklischen ring
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5380858A (en) 1992-04-01 1995-01-10 The University Of Toledo Process for the preparation of intermediates useful for the synthesis of histamine receptor antagonists
US5486526A (en) * 1992-04-01 1996-01-23 The University Of Toledo Histamine H3 -receptor antagonists and therapeutic uses thereof
US5639775A (en) 1992-04-01 1997-06-17 The University Of Toledo 4-[4'-piperodinyl or 3'-pirrolidinyl] substituted imidazoles as H3 -receptor antagonists and therapeutic uses thereof
KR960701858A (ko) 1993-01-25 1996-03-28 가와노 다케히코 이미다졸계 화합물(Imidazole-series compound)
JP3522790B2 (ja) 1993-06-08 2004-04-26 花王株式会社 Ｈ３−レセプター刺激薬
AU7823894A (en) 1993-08-27 1995-03-21 Vrije Universiteit New imidazole derivatives having agonistic or antagonistic activity on the histamine h3 receptor
GB9319534D0 (en) * 1993-09-22 1993-11-10 Boots Co Plc Therapeutic agents
NZ276883A (en) 1993-11-15 1998-08-26 Schering Corp 1h-imidazol-4-yl)alkyl]benzene derivatives
GB9411045D0 (en) * 1994-06-02 1994-07-20 Smithkline Beecham Plc Compounds and use
FR2732017B1 (fr) 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques
US5652258A (en) 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
CA2222099A1 (en) 1995-05-30 1996-12-05 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
CA2222652A1 (en) 1995-06-07 1996-12-19 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
EP0882023B1 (en) 1996-02-09 2003-06-04 James Black Foundation Limited Histamine h 3 receptor ligands
JP3925579B2 (ja) * 1998-02-03 2007-06-06 日本精工株式会社 潤滑剤供給体、並びに前記潤滑剤供給体を備える転がり軸受、リニアガイド装置及びボールねじ装置
EP0982300A3 (en) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6136559A (en) * 1998-10-07 2000-10-24 Ortho Pharmaceutical Corporation DNA encoding as human histamine receptor of the H3 subtype
PL196773B1 (pl) 1999-06-11 2008-01-31 Toyama Chemical Co Ltd Pochodna N-alkiloksyalkilo-N,N-dialkiloaminy lub jej sole oraz środek zawierający ten związek stosowany do leczenia chorób neurodegeneratywnych
GB9924941D0 (en) 1999-10-22 1999-12-22 Univ Manchester Treatment of dyskinesia
US6620839B2 (en) * 2000-07-13 2003-09-16 Abbott Laboratories 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
CA2418369A1 (en) 2000-08-08 2002-02-14 Richard Apodaca Non-imidazole aryloxyalkylamines as h3 receptor ligands
EP1313470A4 (en) 2000-08-17 2005-02-16 Gliatech Inc NEW ALICYCLIC IMIDAZOLE AS H 3 ACTIVE SUBSTANCES
EP1320364A1 (en) * 2000-08-21 2003-06-25 Gliatech, Inc. The use of histamine h3-receptor inverse agonists for the control of appetite and treatment of obesity
PT1373218E (pt) * 2001-03-29 2008-02-21 Ortho Mcneil Janssen Pharm Derivados de imidazolilo úteis como ligandos do receptor h3 de histamina
WO2003044059A1 (en) * 2001-11-15 2003-05-30 Ortho-Mcneil Pharmaceutical, Inc. Agonists of recombinant human histamine h3 receptor
WO2003050099A1 (en) * 2001-12-10 2003-06-19 Ortho-Mcneil Pharmaceutical, Inc. Phenylalkynes
US7279491B2 (en) 2002-10-23 2007-10-09 Janssen Pharmaceutica N.V. Phenylpiperidines and phenylpyrrolidines
US7595316B2 (en) 2003-06-27 2009-09-29 Banyu Pharmaceutical Co., Ltd. Heteroaryloxy nitrogenous saturated heterocyclic derivative
FR2856596B1 (fr) 2003-06-27 2007-04-27 Bioprojet Soc Civ Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes.
SE0302116D0 (sv) * 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体

Also Published As

Publication number Publication date
CA2603656A1 (en) 2006-10-05
AU2006228413C1 (en) 2012-02-02
WO2006103546A3 (en) 2007-03-01
EA016007B1 (ru) 2012-01-30
PL1863487T3 (pl) 2014-10-31
MA29353B1 (fr) 2008-03-03
BRPI0612216A2 (pt) 2010-10-26
WO2006103546A2 (en) 2006-10-05
MX2007012162A (es) 2007-11-22
PT1863487E (pt) 2013-08-29
NO20075086L (no) 2007-12-27
ME01713B (me) 2014-09-20
KR101308527B1 (ko) 2013-09-17
JP5955872B2 (ja) 2016-07-20
ES2426008T3 (es) 2013-10-18
NZ561940A (en) 2010-06-25
CY1114636T1 (el) 2016-10-05
RS52911B2 (sr) 2019-11-29
ES2426008T5 (es) 2020-03-20
CN101171009A (zh) 2008-04-30
HRP20130748T4 (hr) 2019-11-15
CN101171009B (zh) 2012-11-07
SG147415A1 (en) 2008-11-28
TNSN07365A1 (fr) 2008-12-31
UA94902C2 (ru) 2011-06-25
US8486947B2 (en) 2013-07-16
HRP20130748T1 (en) 2013-10-11
EP1863487B1 (en) 2013-05-29
SI1863487T1 (sl) 2013-09-30
RS52911B (sr) 2014-02-28
JP2016106142A (ja) 2016-06-16
PL1863487T5 (pl) 2021-08-09
AU2006228413A1 (en) 2006-10-05
SI1863487T2 (sl) 2019-11-29
BRPI0612216B1 (pt) 2022-04-19
US20090318433A1 (en) 2009-12-24
JP2014062126A (ja) 2014-04-10
DK1863487T4 (da) 2019-10-14
KR20080002904A (ko) 2008-01-04
EP1707203A1 (en) 2006-10-04
EP1863487A2 (en) 2007-12-12
JP5546761B2 (ja) 2014-07-09
NO343603B1 (no) 2019-04-08
CA2603656C (en) 2015-06-16
EP1863487B2 (en) 2019-07-17
JP2008534572A (ja) 2008-08-28
DK1863487T3 (da) 2013-08-12
AU2006228413B2 (en) 2011-09-15
EA200702135A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
PT1613296E (pt) Métodos para o tratamento da doença de parkinson
IL192241A0 (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)-benzamides and the salts thereof
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
IL217385A0 (en) Device for the treatment of obstructive sleep apnea and snoring
IL191864A (en) Transformed 4-amino-pyrolotriazine histories used to treat hyperculturation disorders and diseases associated with new blood vessel formation
EP1957485A4 (en) SUBSTITUTED 4-AMINO-PYRROLOTRIAZINE DERIVATIVES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
WO2006103546A3 (en) Treatment of parkinson's disease, obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3-receptor ligands
ZA200710605B (en) New 2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
ZA200909191B (en) Catecholamine derivatives useful for the treatment of parkinson's disease
IL184059A0 (en) Crystal and salt of 1-cyclopropylmethyl-4-[2-(3,3,5,5)-tetramethylcyclohexylphenyl]piperazine
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
IL177787A0 (en) 1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
EP1753446A4 (en) ALPHA-1 GLYCOPROTEIN ACID FOR THE TREATMENT OF DIABETES
IL184849A0 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
DE602006001590D1 (de) 7-(2-(4-(3-trifluormethylphenyl)-1,2,3,6-tetrahydropyrid-1-yl)ethyl)isochinolin-besylatsalz, dessen herstellung und dessen therapeutische verwendung
SI1907374T1 (sl) Derivati benzilpiperazina uporabni za zdravljenje gastrointestinalnih motenj
IL178444A0 (en) 6-substituted pyridoindolone derivatives production and therapeutic use thereof
SG126063A1 (en) Methods for the treatment of insulin resistance and disease states characterized by insulin resistance
PL1732557T3 (pl) Pochodne 1-[2H-1-benzopiran-2-on-8-ylo]-piperazyny do leczenia zaburzeń ruchowych
GB0410101D0 (en) Parkinson's disease
EP1863510A4 (en) METHOD FOR TREATING PARKINSON DISEASE
EP1926486A4 (en) NOVEL (S) -2,6-DIAMINO-4,5,6,7-TETRAHYDROBENZOTHIAZOLE MONOTARTRATE POLYMORPHS AND METHODS OF MAKING AND USING THE SAME
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
IL164500A0 (en) 2,5-Bis-diamine-Ä1,4Übenzoquinonic derivatives, useful for the treatment of alzheimers disease, method for disease, method for preparing them and intermediates of said method